BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases

Reuters
2024-11-08

Nov 8 (Reuters) - Allovir Inc :

* ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF THE RETINA

* ALLOVIR INC - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST

* ALLOVIR INC - STOCKHOLDERS TO OWN 25.05% OF COMBINED COMPANY POST-MERGER

* ALLOVIR INC - COMBINED COMPANY TO BE LED BY KALARIS CEO ANDREW OXTOBY

* ALLOVIR INC - COMBINED COMPANY TO OPERATE AS KALARIS THERAPEUTICS, INC. AND TRADE AS KLRS

* ALLOVIR INC - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED IN Q3 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10